Receptor News and Research

RSS

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

Diuretics effective as second-line agents in treating high blood pressure

A new review shows that diuretics — drugs often recommended as a first-line treatment for high blood pressure — are also effective when added as a second agent to other blood-pressure lowering drugs.

7 Oct 2009

New findings on Alzheimer's disease suggest a possible way for treatment

The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

7 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

GeneMedRx software warns patients and physicians if tamoxifen benefit is at risk

One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.

3 Oct 2009

Critical biochemical pathways linked to the aging of human muscle identified

A study led by researchers at the University of California, Berkeley, has identified critical biochemical pathways linked to the aging of human muscle. By manipulating these pathways, the researchers were able to turn back the clock on old human muscle, restoring its ability to repair and rebuild itself.

3 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Role of gene that could influence fertility identified in mice

Virginia Commonwealth University researchers have identified the role of a gene in regulating molecular signals involved with ovarian follicle development, which may one day help shed light on some of the causes of fertility issues in humans.

3 Oct 2009

NK cells keep T cells in check: Study

Natural killer, or NK cells, are part of our innate immune system. A healthy body produces them to respond early during infection. They are activated and they kill cells infected with a given virus.

3 Oct 2009

ALL initiative three-year clinical observational study results published

A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.

3 Oct 2009

Study reveals the importance of cholestrol derivative in brain cell formation

A derivative of cholesterol is necessary for the formation of brain cells, according to a study from the Swedish medical university Karolinska Institutet. The results, which are published in the journal Cell Stem Cell, can help scientists to cultivate dopamine-producing cells outside the body.

2 Oct 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases.

1 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Membrane-bound Fas ligand is essential for cell death: Researchers

Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also called apoptosis).

1 Oct 2009

Critical biochemical pathways linked to the aging of human muscle identified

30 Sep 2009

University scientists achieve breakthrough in brain research

Chaos brews in the brains of newborns: the nerve cells are still bound only loosely to each other. Under the leadership of Academy Research Fellow Sari Lauri, a team of researchers at the University of Helsinki has been studying for years how a neural network capable of processing information effectively is created out of chaos. The team has now found a new kind of mechanism that adjusts the functional development of nerve cell contacts.

30 Sep 2009